Trials / Completed
CompletedNCT00286806
A Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer
An Open-Label, Multicenter, Phase I/II Study of Single-Agent AT-101 in Men With Hormone Refractory Prostate Cancer (HRPC) and Rising Prostate Specific Antigen (PSA) Levels Who Have Not Received Prior Chemotherapy
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 27 (planned)
- Sponsor
- Ascenta Therapeutics · Industry
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This is an open-label, multicenter Phase I/II study to evaluate the safety and efficacy of single-agent AT-101 in men with hormone-refractory prostate cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | AT-101 |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2007-06-01
- Completion
- 2007-06-01
- First posted
- 2006-02-06
- Last updated
- 2010-08-24
Locations
4 sites across 1 country: United States
Source: ClinicalTrials.gov record NCT00286806. Inclusion in this directory is not an endorsement.